Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer

Background: Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0...

Full description

Saved in:

Bibliographic Details
Main Author:	Mantziari, Styliani (author)
Other Authors:	Gronnier, Caroline (author), Renaud, Florence (author), Duhamel, Alain (author), Théreaux, Jérémie (author), Brigand, Cécile (author), Carrère, Nicolas (author), Lefevre, Jérémie H. (author), Pasquer, Arnaud (author), Demartines, Nicolas (author), Collet, Denis (author), Meunier, Bernard (author), Mariette, Christophe (author)
Format:	article
Published:	2017
Online Access:	http://hdl.handle.net/10725/14208 https://doi.org/10.1097/SLA.0000000000002402 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://pubmed.ncbi.nlm.nih.gov/28742698/
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer

Similar Items